Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Invivyd, Inc. - Common Stock (NQ:IVVD)

1.665 +0.015 (+0.91%)
Streaming Delayed Price Updated: 9:37 AM EST, Nov 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Invivyd, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
INVIVYD ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Invivyd, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (IVVD) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Bronstein, Gewirtz & Grossman, LLC Notifies Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (IVVD) Investors of Class Action and to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
NATIONALLY RANKED ROSEN LAW FIRM Encourages Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IVVD, ADGI
From Rosen Law Firm
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (IVVD) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Invivyd, Inc. (IVVD) f/k/a Adagio Therapeutics, Inc.
From Robbins LLP
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (IVVD) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
IVVD INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Case
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshop
From Invivyd
Via GlobeNewswire
Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer
From Invivyd
Via GlobeNewswire
Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19
From Invivyd
Via GlobeNewswire
NASDAQ:IVVD Investor Alert: Investigation over Potential Wrongdoing at Invivyd, Inc.
San Diego, CA -- (SBWIRE) -- 11/11/2022 -- Certain directors of Invivyd, Inc. are under investigation over potential breaches of fiduciary duties. 
Via SBWire
Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Invivyd to Participate in Fireside Chat at the Jefferies London Healthcare Conference
From Invivyd
Via GlobeNewswire
Invivyd Announces the Appointment of Christine Lindenboom to Board of Directors
From Invivyd
Via GlobeNewswire
Invivyd, Inc. (NASDAQ:IVVD) Shareholder Notice: Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 10/17/2022 -- Invivyd, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery Platform
From Invivyd
Via GlobeNewswire
Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022
From Invivyd
Via GlobeNewswire
In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews David Hering CEO, Invivyd Inc.
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.